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SRF in 80% of the treated eyes; the amount of fluid increased 
at months 4, 6 and 8 with troughs in between. Whereas fibro-
vascular PEDs remained stable after the loading phase, se-
rous PEDs displayed a seesaw pattern. Patients without reti-
nal pigment epithelium (RPE) atrophy at the end of the 
1-year period had significantly better BCVA compared to pa-
tients with RPE atrophy (p = 0.03).  Conclusion: Despite sig-
nificant overall BCVA gain, bimonthly intervals seem insuf-
ficient to maintain the morphological improvements after 
the initial loading dose with intravitreal aflibercept. 
 © 2015 S. Karger AG, Basel 
 Introduction 
 Age-related macular degeneration (AMD) is a chronic 
and degenerative disease and one of the leading causes of 
legal blindness in patients over the age of 60 years in the 
industrialized world  [1] . The most severe vision loss oc-
curs in the neovascular form of AMD, associated with 
intraretinal fluid (IRF) or subretinal fluid (SRF) caused by 
choroidal neovascularisation (CNV). Current treatment 
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 Abstract 
 Purpose: To assess the effect of a bimonthly treatment regi-
men with intravitreal aflibercept on retinal fluid and pigment 
epithelial detachment (PED) in patients with neovascular 
age-related macular degeneration (AMD).  Methods: Twen-
ty-six treatment-naive eyes of 26 patients with choroidal 
neovascularisation secondary to AMD were included. The 
patients received three initial monthly (mean 30 days) intra-
vitreal injections of aflibercept followed by a bimonthly 
(mean 62 days) fixed regimen for a total of 1 year. Best-cor-
rected visual acuity (BCVA) and optical coherence tomogra-
phy (OCT) measurements were recorded at monthly inter-
vals. In addition, the presence of intraretinal fluid (IRF) or 
subretinal fluid (SRF) or a combination of both as well as se-
rous and fibrovascular PEDs were assessed.  Results: The 
mean patient age was 80 years (range 54–93). There were 14 
male and 12 female patients. The mean gain in BCVA at 1 
year was 9.3 letters (SEM ±3) with a mean reduction of the 
central retinal thickness of 154 μm (SEM ±50). After 3 month-
ly injections of aflibercept, there was resolution of IRF and 
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options for the neovascular component consist of antian-
giogenic substances (anti-VEGF) that are able to reduce 
intraretinal and subretinal leakage and oedema. Anti-
VEGF therapies, such as intravitreal ranibizumab (Lu-
centis; Genentech, Inc., South San Francisco, Calif., USA) 
and aflibercept (Regeneron Pharmaceuticals, Inc., Tarry-
town, N.Y., USA, and Bayer HealthCare, Berlin, Germa-
ny), have been shown to restore macular morphology and 
consecutively to preserve or even improve visual acuity in 
multiple clinical trials  [2, 3] .
 To reduce the burden of monthly intravitreal injec-
tions, new regimens that may provide equivalent efficacy 
and anatomic control compared to monthly ranibizu-
mab have been studied (PIER/EXCITE)  [4, 5] . However, 
none of these regimens achieved a similar long-term vi-
sion gain compared to monthly intravitreal ranibizumab 
injections. More recently, the Comparison of AMD 
Treatments Trials (CATT)  [6, 7] has compared monthly 
ranibizumab to pro re nata (PRN) regimens with month-
ly visits. Anatomical criteria were used to decide on the 
need for retreatment. Here, PRN ranibizumab was non-
inferior to the monthly gain, however, with a mean best-
corrected visual acuity (BCVA) gain of 1.7 letters less 
than that of the monthly standard treatment. With the 
introduction of aflibercept following the two pivotal 
VIEW studies  [2, 3] , showing non-inferiority of 8-week 
injections compared to monthly ranibizumab injections, 
the need for monthly follow-up visits became redundant. 
Although the VIEW studies used an 8-week (average of 
56 days) retreatment regimen, a bimonthly retreatment 
regimen (average of 61 days) is often more practicable 
due to organisational reasons in real life. Aflibercept is a 
fusion protein of key domains from human VEGF recep-
tors 1 and 2  [8] and has been shown to have a signifi-
cantly higher binding affinity to VEGF than ranibizumab 
 [9–11] .
 Here, we report on morphological and functional out-
comes using a fixed bimonthly aflibercept treatment reg-
imen at a tertiary referral centre.
 Methods 
 Participants 
 In this retrospective interventional study, a consecutive series 
of treatment-naive patients receiving intravitreal aflibercept for 
exudative AMD were identified from the procedure logs at the De-
partment of Ophthalmology of the University Hospital Bern. All 
patients had clinically confirmed exudative AMD and had spectral 
domain optical coherence tomography (SD-OCT) imaging per-
formed before receiving their initial treatment. All patients re-
ceived an identical loading dose of three consecutive monthly in-
travitreal injections followed by bimonthly maintenance treat-
ment with aflibercept. Ethics approval (KEK-No. 093/13) to 
conduct this study was obtained from the local ethics committee, 
which is working in accordance with ICH-GCP guidelines. The 
need for written consent from each individual patient was waived 
because of the retrospective nature of the study.
 Image Acquisition 
 Spectralis SD-OCT (Heidelberg Engineering, Heidelberg, Ger-
many; Software version 5.3) scans were acquired using an estab-
lished protocol consisting of both cross-hair scans and volume 
scans. The cross-hair scan consisted of a vertical and a horizontal 
scan. For the volume scan of 20° × 20°, 49 frames spaced 121 μm 
and each consisting of 512 A-scans were acquired. The automated 
real-time was set between 6 and 12 scans to reduce noise.
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 Fig. 1. Functional and anatomical results using a fixed bimonthly 
maintenance treatment with aflibercept for exudative AMD.
 a Mean change in BCVA from baseline (BL).  b Mean change in 
CRT from baseline (BL) (arrows show injection frequency). 
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 Image Analysis 
 Each imaging data set was reviewed by two independent as-
sessors, and the presence of SRF or IRF was evaluated at each 
visit. In addition, the presence of serous (evidenced by hypore-
flective internal reflectivity) or fibrovascular (evidenced by het-
erogeneous internal reflectivity)  [12] pigment epithelial detach-
ments (PEDs) was recorded for each monthly follow-up visit (ex-
cept for month 10). Central retinal thickness (CRT) was measured 
automatically as the distance from the internal limiting mem-
brane of the retina to the outer border of the retinal pigment 
epithelium (RPE) excluding any sub-RPE structures like CNV 
membranes. Using the Heidelberg Eye explorer software (version 
1.7.1.0), the area (measured in square millimetre) of the PED was 
measured in the horizontal cross-hair OCT scan and the corre-
sponding follow-ups. Then, the subfoveal choroidal thickness 
was measured from the Bruch membrane to the inner scleral 
margin.
 In addition to monthly SD-OCT imaging, BCVA was mea-
sured monthly according to a standardized refraction procedure 
using ETDRS charts at 1 and 4 m. Atrophy of the RPE within the 
macula (defined as within the volume scan of 6 × 6 mm) was grad-
ed by two independent assessors at baseline and at year 1 using 
either autofluorescence or infrared OCT images. For patients de-
veloping atrophy over the follow-up period, we assessed the OCT 
scans performed at control visits to evaluate the time point of at-
rophy development.
 The last observation carried forward approach was used. Twen-
ty-four patients completed the 12 months, whereas 2 patients dis-
continued treatment at 10 and 9 months, respectively.
 Statistical Analysis 
 A statistical analysis was performed using the Prism Graph 
Pad ® commercial software package (Prism 5; GraphPad Software 
Inc., La Jolla, Calif., USA). BCVA and CRT data was analysed by 
ANOVA or paired t test as indicated (Wilcoxon matched-pairs 
signed-rank test for nonparametric data). For comparison be-
tween groups, an unpaired t test was employed. For correlation, 
Spearman nonparametric analysis (ρ) was used. p < 0.05 was con-
sidered statistically significant.
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 Fig. 2. The response of IRF and SRF to aflibercept using a fixed 
treatment regimen is presented.  a Representative OCT scans at 
baseline (BL), months 1, 2 and 4.  b1 Percentage of patients with 
IRF and SRF (total fluid).  b2 Percentage of patients with either SRF 
or IRF at each month (arrows show injection frequency). 
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 Results 
 Twenty-six patients were included in this study. The 
mean patient age at the time of diagnosis of exudative 
AMD was 80 years (range 54–93, 14 female patients). The 
mean BCVA at baseline was 52 ETDRS letters (range 
5–80), and the CRT was 413 μm (range 242–760). BCVA 
increased from a mean of 52 ± 4 (SEM) letters at baseline 
to 63 ± 4 at 12 months (p = 0.003). CRT decreased from 
413 ± 24 μm at baseline to 305 ± 23 μm at 12 months
(p = 0.002). The change in BCVA and CRT in our patient 
cohort is summarized in  figure 1 .
 At baseline, all patients had either IRF (70%) or SRF 
(70%) or a combination of both (100%) ( fig. 2 a). After the 
loading phase, consisting of three monthly injections, the 
percentage of patients displaying IRF was 12%, and the 
percentage of patients having SRF was 4% ( fig. 2 b1, b2). 
No fluid was detected in 84% of patients after the loading 
phase. After switching to the bimonthly fixed mainte-
nance regimen, the percentage of patients displaying SRF 
or IRF increased between the injections following a see-
saw pattern ( fig.  2 b1, b2). This pattern was more pro-
nounced with IRF than with SRF. Nine out of 26 patients 
(34%) had complete regression of IRF or SRF after the 
loading phase. Subgroup analysis showed that eyes that 
remained without fluid after the loading phase responded 
similarly to aflibercept with regard to vision gain and 
CRT decrease compared to eyes having recurrent IRF or 
SRF ( fig. 3 a, b).
 We next analysed morphological changes in the sub-
RPE space. Longitudinal measurements of serous and fi-
brovascular PEDs showed a marked decrease during the 
loading phase with aflibercept in both groups (p = 0.04 
and p = 0.15, respectively;  fig. 4 a). Whereas the fibrovas-
cular PED remained fairly stable over the course of the 
year under a bimonthly fixed regimen, the serous PEDs 
displayed a seesaw pattern with increase in serous fluid in 
the treatment-free intervals and a decrease in PED height 
1 month after injection ( fig. 4 b1). Eyes with serous PEDs 
had a significantly higher decrease in CRT from baseline 
compared to eyes with fibrovascular PEDs. However, 
there was only a tendency towards more letter gain in eyes 
with fibrovascular PEDs compared to eyes with serous 
PEDs over the course of 1 year ( fig. 4 b2). Under treatment 
with aflibercept, choroidal thickness did not decrease sig-
nificantly over the course of 1 year ( fig. 4 c).
 Nine eyes (34%) had areas of atrophy at baseline 
( fig. 5 a). During treatment, one eye developed atrophy at 
1 month and two eyes at 2 months after the initiation of 
treatment with intravitreal aflibercept. At 1 year, 13 eyes 
(50%) displayed atrophy within the volume scan area. 
Subgroup analysis showed that patients without atrophy 
at 1 year did significantly better in terms of BCVA com-
pared to patients having atrophy (p = 0.03;  fig. 5 b). There-
after, we analysed whether the presence of either IRF or 
SRF correlated with the presence of atrophy at the end of 
year 1. We found a significant but rather weak correlation 
of the presence of atrophy with SRF (r = 0.45, p = 0.02) 
but not with IRF (r = –0.21, n.s.).
 Discussion 
 We report here on functional and anatomical out-
comes using a fixed bimonthly treatment regimen for ex-
udative AMD with intravitreal aflibercept. Whereas the 
pivotal studies of aflibercept used an 8-week (56 days) 
retreatment interval, the mean treatment interval in our 
study cohort was 2 months (61 days). The gain in ETDRS 
letters in our study at 1 year was 9.3, which is slightly bet-
ter than the 8.4 seen for the 8-week aflibercept regimen in 
the VIEW studies. In our study, there was a low percent-
age of eyes displaying persisting IRF or SRF after the load-
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 Fig. 3. Mean change in BCVA ( a ) and CRT ( b ) from baseline (BL) 
in patients with recurrent fluid (wet) or without recurrent fluid 
(dry). Letter gain and decrease in CRT were not statistically differ-
ent between the subgroups (analysed by one-way ANOVA). 
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ing phase. After three injections, only 12% of eyes dis-
played IRF or SRF on SD-OCT. In the VIEW studies, the 
proportion of patients with no retinal fluid on time-do-
main OCT ranged from 60.3 to 72.4% at week 52, which 
is in keeping with our results at 1 year  [2] .
 Several salient OCT features merit further discussion, 
which have not received much attention in the literature 
so far. In the first instance, our data shows that despite 
excellent functional visual outcomes, a bimonthly treat-
ment regimen leads not only to fluctuations in IRF and 
SRF but also in serous PEDs. The response of SRF to in-
travitreal aflibercept in our patient cohort is very rapid 
and remains stable during the maintenance phase with 
extended intervals. However, IRF is fluctuating to a great-
er extent and seems to be more prone to recurrence dur-
ing the bimonthly treatment intervals. However, we did 
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 Fig. 4. The response of PED to aflibercept 
using a fixed treatment regimen is present-
ed.  a Representative case history showing 
combined serous (S) and fibrovascular (F) 
PED at baseline (BL) and months 3, 4, 5, 8 
and 10.  b1 Quantitative analysis of PEDs 
using the horizontal single scan in the res-
can registration mode (the baseline was set 
at 1.0).  b2 BCVA gain and CRT decrease at 
month 12 in patients with serous PED (S;
n = 8) and fibrovascular PED (F; n = 12) at 
baseline (unpaired t test; n.s. = not signifi-
cant).  c Quantitative analysis of the mean 
choroidal thickness at each month. 
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6
not find significant differences in BCVA between eyes 
with recurrent fluid and eyes without recurrent fluid after 
the loading phase.
 Previous reports on the effect of anti-VEGF treatment 
of PEDs include ranibizumab and bevacizumab. How-
ever, to our knowledge, there is no detailed report on the 
effect of aflibercept on either serous or fibrovascular 
PEDs. We showed that serous PEDs respond well to 
aflibercept and have not found any signs of RPE rips in 
our patient cohort. However, as with IRF, a bimonthly 
treatment interval leads to recurrence of serous PEDs be-
tween injections. In contrast, fibrovascular PEDs dis-
played a robust reduction in height during the loading 
phase and did not show fluctuations thereafter. An inter-
esting finding that needs confirmation in a larger patient 
cohort is that, although eyes with fibrovascular PEDs 
showed less final CRT decrease compared to eyes with 
serous PEDs or no PEDs at all, the mean visual acuity gain 
seemed to be slightly better in eyes with fibrovascular 
PEDs when compared to eyes with serous PEDs.
 Another finding of this study is that patients with RPE 
atrophy had a less favourable course of vision improve-
ment and significantly less BCVA gain at 1 year compared 
to patients without RPE atrophy. A similar observation 
has been reported in the 7-year outcome of ranibizumab 
treatment for exudative AMD  [13] . In our study, 3 pa-
tients (11%) developed atrophy during the 1-year treat-
ment with aflibercept. However, atrophy became visible 
already after the first injection at month 1 in one eye and 
after the second injection at month 2 in the other two 
eyes. It seems to be unlikely that atrophy develops in such 
a short period of time. Therefore, we assume that atrophy 
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 Fig. 5. Presence of atrophy of the RPE and influence on BCVA.
 a Representative case history showing 2 patients with RPE atrophy 
at baseline (BL) and at 1 year (1y).  b Quantitative analysis of BCVA 
in patients with and without atrophy at 1 year ( *  p = 0.03). 
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was to a large degree pre-existent but masked by IRF or 
SRF. An intriguing finding is the correlation of SRF with 
the presence of atrophy at the end of year 1. This may be 
due to a more pronounced dysfunction of the RPE, caus-
ing accumulation of fluid in the subretinal space as com-
pared to patients with IRF, where structural changes 
within the retina may play a bigger role.
 Our study has several weaknesses, mainly due to its 
retrospective nature and the relatively small number of 
subjects. This was in part due to the strict inclusion crite-
ria as all follow-up scans had to be acquired with the res-
can registration feature. Furthermore, PED was mea-
sured using the horizontal single-line OCT scan in the 
rescan mode, and therefore measurements only provide 
an approximate value of the actual PED size.
 The VIEW studies have shown that a bimonthly treat-
ment regimen results in excellent functional results. 
However, on a morphological level, the VIEW studies 
show that bimonthly injections lead to fluctuations in 
CRT. These fluctuations in CRT are in keeping with our 
study. Analysis of central thickness fluctuations in our 
cohort showed that this was mainly driven by fluid fluc-
tuations in the intraretinal layers as well as the sub-RPE 
space. On the contrary, bimonthly treatment with afliber-
cept resulted in excellent BCVA gain over the course of 1 
year and, therefore, represents a good treatment option 
for patients with neovascular AMD.
 Clinical data from PRN or treat-and-extend treatment 
regimens will provide further information on which in-
tervals are optimal for intravitreal aflibercept in order to 
maintain morphological stability. 
 In conclusion, using a bimonthly regimen with afliber-
cept for neovascular AMD, we found marked fluctuations 
in IRF and SRF as well as serous PEDs.
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